Experimental chemo drug tested for advanced breast cancer
NCT ID NCT04796324
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the chemotherapy drug ixabepilone in 13 patients with metastatic breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow the disease. The study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ixabepilone (a chemotherapy drug)
What this could lead to
If successful, this could provide a treatment option for metastatic breast cancer patients who have not responded to standard chemotherapies.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. Ixabepilone may not work for all patients and can cause side effects like nerve damage and low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Antwerp, Edegem, 2650, Belgium
-
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, G12 0YN, United Kingdom
-
CHU de Liege, Oncology Department
Liège, 4000, Belgium
-
Cancer Institute Singleton Hospital
Swansea, Wales, SA2 8QA, United Kingdom
-
Centrum Onkologii Ziemi Lubelskiej im.
Lublin, 20-090, Poland
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Clin. Univ. Saint-Luc
Brussels, 1200, Belgium
-
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, EH4 2XR, United Kingdom
-
Ikazia Hospital Rotterdam
Rotterdam, 3083, Netherlands
-
Medway NHS Foundation Trust
Gillingham, Kent, ME7 5NY, United Kingdom
-
Modena University Hospital
Modena, 41124, Italy
-
Nottingham University Hospitals
Nottingham, Nottingham, NG5 1PB, United Kingdom
-
Oddział Onkologii Klinicznej, Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu
Poznan, 61-848, Poland
-
Onze-Lieve-Vrouwziekenhuis
Aalst, Aalst, 9300, Belgium
-
Somerset NHS Foundation Trust
Taunton, Somerset, TA1 5DA, United Kingdom
-
St James Hospital
Leeds, LS9 7TF, United Kingdom
-
Tampere University Hospital
Tampere, Pirkanmaa, 33520, Finland
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
-
Wojewodzki Szpital Specjalietyczny
Biała Podlaska, Biala Podlaska, 21-500, Poland